No Data
CONBA Pharma Gets Regulatory Nod to Make Changes to Amikacin Sulfate Injection
Zhejiang Conba Pharmaceutical (600572.SH): Amikacin Sulfate Injection pharmaceutical passed the generic drug consistency evaluation
Zhejiang Conba Pharmaceutical (600572.SH) announced on December 3 that the company has received the Drug Administration of China's approval for the issuance of the Approval Notice for the supplementary application of Amikacin Sulfate Injection (hereinafter referred to as "the pharmaceutical"), which has passed the evaluation of generic drug quality and efficacy consistency. Amikacin Sulfate is an aminoglycoside antibiotic, clinically applicable to severe infections caused by sensitive gram-negative rods such as Pseudomonas aeruginosa and other Pseudomonas species, Escherichia coli, and Staphylococcus species (methicillin-sensitive strains), such as septicemia or sepsis, bacterial endocarditis, etc.
Zhejiang CONBA PharmaceuticalLtd's (SHSE:600572) Earnings Have Declined Over Five Years, Contributing to Shareholders 16% Loss
Zhejiang CONBA Pharmaceutical Gets Approval for Hair Loss Cream in China
Zhejiang Conba Pharmaceutical (600572.SH): Minoxidil lotion obtained pharmaceutical registration certificate.
On November 27, Geelong reported that zhejiang conba pharmaceutical (600572.SH) announced that its wholly-owned subsidiary, Hangzhou Zhejiang Conba Pharmaceutical Co., Ltd., has received the "Drug Registration Certificate" for 5% and 2% minoxidil lotion issued by the National Medical Products Administration. The original research of minoxidil lotion is by the USA company Johnson & Johnson. The 2% lotion was approved for listing in the USA in 1988 for the treatment of hair loss in men and women; the 5% lotion was approved for listing in the USA in 1997, indicated for male hair loss.
Market Still Lacking Some Conviction On Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572)
Zhejiang CONBA Pharmaceutical Co.,Ltd.'s (SHSE:600572) Shares Lagging The Market But So Is The Business
